Prosecution Insights
Last updated: April 19, 2026
Application No. 18/195,419

RED BEET PIGMENT COMPOSITION

Final Rejection §101§102§112
Filed
May 10, 2023
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF COPENHAGEN
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
572 granted / 1058 resolved
-5.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
1125
Total Applications
across all art units

Statute-Specific Performance

§101
9.5%
-30.5% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1058 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The amendment filed October 28, 2025 has been received and entered. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior Office action. Any rejection set forth in a previous Office action that is not specifically set forth below is withdrawn. 3. Claims 1, 2, and 4-7 are pending. Election/Restrictions 4. In the reply filed on May 30, 2025, applicant elected species i), wherein the betalain pigment composition has a betanin to vulgaxanthin ratio increased by at least 5% higher (w/w), preferably at least 10% higher (w/w), even more preferably at least 15% higher (w/w) as compared to a betalain pigment composition obtained without the use of an ethylene-generating compound, without traverse 5. Claims 1, 2, and 4-7 are examined on the merits solely in regards to the elected species. Claim Rejections - 35 USC § 112 6. Claims 1, 2, and 4-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. As discussed in the previous Office action, claim 1, at lines 2-3, is indefinite because the phrase “comprising betanin, betalain, and vulgaxanthin” is confusing. It is unclear if the requirement that the composition contain “betalain” indicates that a third betalain pigment in addition to the betanin and vulgaxanthin is required for the composition. Applicant did not specifically address this rejection in the response and the indefinite language still appears in the claims. Claim Rejections - 35 USC § 101 7. Claims 1, 2, and 4-7 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural product without significantly more for the reasons set forth in the previous Office action. All of applicant’s arguments regarding this ground of rejection have been fully considered but are not persuasive. Applicant argues that the claims as amended as not directed to a naturally occurring product because a red beet plant with a comparatively 15% higher ratio of betanin to vulgaxanthin is not naturally occurring. However, both betanin and vulgaxanthin are naturally occurring compounds. When a claim recites naturally occurring products, MPEP § 2106.04(c)(I) states that “if the nature-based product limitation is not naturally occurring, for example due to some human intervention, then the markedly different characteristics analysis must be performed to determine whether the claimed product limitation is a product of nature exception…”. To perform the markedly different characteristic analysis, MPEP § 2106.04(c)(II) states “The markedly different characteristics analysis compares the nature-based product limitation to its naturally occurring counterpart in its natural state. Markedly different characteristics can be expressed as the product’s structure, function, and/or other properties…”. In this case, the closest occurring natural counterpart for vulgaxanthin and betanin are the compounds themselves. There is no evidence to show that combining these two compounds in amounts that meet the claimed ratios produces a product with a markedly distinct characteristic. Thus, the claims as amended as still considered to be directed to ineligible subject matter. Claim Rejections - 35 USC § 102 8. Claim(s) 1, 2, and 4-7 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Czyzowska (Eur. Food Res. Technol. (2006), vol. 223: 110-116, 7 pages) for the reasons set forth in the previous Office action. All of applicant’s arguments regarding this ground of rejection have been fully considered but are not persuasive. Applicant argues that the reference does not teach the claimed invention because the reference does not teach that the betanin to vulgaxanthin ratio is increased by at least 15%. However, Table 5 in the reference shows that the control beet juice has a betanin concentration of 49.60 and a vulgaxanthin concentration of 36.36. Juice fermented with Lactobacillus paracasei/casei strains 0923 and 0920 have a betanin concentration of 192.58 and 185.81, respectively, and a vulgaxanthin concentration of 17.74 and 18.55, respectively. These are 10.8:1 and 10.1 ratios of betanin to vulgaxanthin, respectively. The content of betanin in the 0923 fermented juice is increased by 26% while the content of vulgaxanthin is decreased by 48%. The content of betanin in the 0920 fermented juice is increased by 26% while the content of vulgaxanthin is decreased by 50%. Thus, these red beet juices, in comparison to the control, showed over an increase in the betanin to vulgaxanthin ratio that meets the limitations of claim 1 and a betanin to vulgaxanthin ratio that meets the limitations of claim 2. Thus, applicant’s arguments are not persuasive. 9. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

May 10, 2023
Application Filed
Jul 31, 2025
Non-Final Rejection — §101, §102, §112
Oct 28, 2025
Response Filed
Feb 04, 2026
Final Rejection — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594313
COMPOSITION FOR RELIEVING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS COMPRISING A MIXED EXTRACT OF HOP AND CYNANCHUM WILFORDII AND METHOD FOR TREATING OR ALLEVIATING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS USING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12582674
Methods and Treatment of Trauma
2y 5m to grant Granted Mar 24, 2026
Patent 12569527
TETRASELMIS CHUII (T. CHUII) FOR THE TREATMENT OF MALE INFERTILITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564606
PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS
2y 5m to grant Granted Mar 03, 2026
Patent 12564551
Composition or oat extract comprising avenanthramide and ß-glucan
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1058 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month